Skip to content
DataLookout
Menu

SKYSCRAPER-07NCT04543617

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 54 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Primary completion date changed from estimate of Mar 31, 2027 to Jul 22, 2026
    • Study sites: 167 to 166
    v54
  2. Minor Study sites: 165 to 167v52
  3. Minor Study sites revised (165)v51
  4. Minor Study sites: 166 to 165v50
  5. Minor Study sites revised (166)v49
Show 41 earlier versionsHide 41 earlier versions
  1. Minor Study sites: 163 to 166v48
  2. Minor Study sites: 179 to 163v47
  3. Minor Study sites: 180 to 179v46
  4. Minor Study sites: 181 to 180v44
  5. Minor Study sites: 185 to 181v42
  6. Minor Study sites: 190 to 185v41
  7. Minor Study sites: 193 to 190v40
  8. Notable Primary and study completion dates pushed to Mar 31, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 750 to confirmed 760
    • Study sites: 231 to 193
    v39
  9. Minor Site details revised at 29 of 231 sitesv38
  10. Minor Site details revised at 27 of 231 sitesv37
  11. Minor Study sites revised (231)v36
  12. Minor Site details revised at 9 of 231 sitesv35
  13. Minor Site details revised at 12 of 231 sitesv34
  14. Minor Site details revised at 10 of 231 sitesv33
  15. Minor Site details revised at 14 of 231 sitesv32
  16. Minor Study sites revised (231)v31
  17. Minor Study sites revised (231)v30
  18. Minor Study completion date: Dec 26, 2025 to Jun 27, 2025
    • Study sites revised (231)
    v29
  19. Minor Site details revised at 16 of 231 sitesv28
  20. Minor Study sites: 230 to 231v27
  21. Minor Study sites: 229 to 230v26
  22. Minor Study sites: 228 to 229v25
  23. Minor Study sites: 224 to 228v24
  24. Minor Study sites: 223 to 224v23
  25. Minor Site details revised at 14 of 223 sitesv22
  26. Minor Study sites: 220 to 223v21
  27. Minor Site details revised at 8 of 220 sitesv20
  28. Minor Study sites: 218 to 220v19
  29. Minor Study sites: 208 to 218v18
  30. Minor Study sites: 206 to 208v17
  31. Minor Study sites: 220 to 206v16
  32. Minor Study sites: 218 to 220v15
  33. Notable Eligibility criteria expanded, about 2 words
    • Study sites: 215 to 218
    v14
  34. Minor Study sites: 214 to 215v12
  35. Minor Site details revised at 13 of 214 sitesv11
  36. Minor Study sites: 213 to 214v10
  37. Minor Study sites: 211 to 213v9
  38. Minor Study sites: 213 to 211v8
  39. Minor Study sites: 212 to 213v7
  40. Minor Study sites revised (212)v6
  41. Minor Study sites: 213 to 212v5
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Arm A vs Arm C: Investigator-Assessed Progression-Free Survival (PFS)
Timeframe: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Arm A vs Arm C: Overall Survival (OS)
Timeframe: From randomization to death from any cause (up to approximately 6 years)
Arm B vs Arm C: OS
Timeframe: From randomization to death from any cause (up to approximately 6 years)

Secondary (15)

Arm B vs Arm C: Investigator-Assessed PFS
Arm A vs Arm B: Investigator-Assessed PFS
Arm A vs Arm B: OS
Independent Review Facility (IRF)-Assessed PFS
Investigator-Assessed Confirmed Objective Response Rate (ORR)
Show 10 moreShow less
IRF-Assessed Confirmed ORR
Investigator-Assessed Duration of Objective Response (DOR)
IRF-Assessed DOR
Percentage of Participants With Clinically Meaningful Changes in Physical Functioning, Role Functioning, Quality of Life (QoL) as Measured by EORTC QLQ-C30
Percentage of Participants With Clinically Meaningful Changes in Dysphagia as Measured by EORTC QLQ-OES18
Percentage of Participants With Adverse Events (AEs)
Serum Concentration of Tiragolumab
Serum Concentration of Atezolizumab
Percentage of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Percentage of Participants With ADAs to Atezolizumab

Arms and interventions

Arm A: Tiragolumab + AtezolizumabExperimental

Participants will receive atezolizumab followed by tiragolumab.

Arm B: Tiragolumab Placebo + AtezolizumabExperimental

Participants will receive atezolizumab followed by tiragolumab matching placebo.

Arm C: Tiragolumab Placebo + Atezolizumab PlaceboPlacebo comparator

Participants will receive matching placebos to tiragolumab and atezolizumab.

Drugs: Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo

Sites

166 sites in 28 countries

China 35, Japan 15, France 10, Spain 9, Russia 8, Germany 7, South Korea 7, Turkey (Türkiye) 7, Poland 6, Taiwan 6, United Kingdom 6, Austria 4, Italy 4, Thailand 4, Ukraine 4, Argentina 3, Australia 3, Belgium 3, Greece 3, Israel 3, Morocco 3, Portugal 3, South Africa 3, United States 3, Hungary 2, Kenya 2, Switzerland 2, New Zealand 1